Charles River Laboratories International (NYSE:CRL) PT Lowered to $190.00 at Robert W. Baird

Charles River Laboratories International (NYSE:CRL - Free Report) had its price objective lowered by Robert W. Baird from $191.00 to $190.00 in a research note released on Friday morning, Benzinga reports. The brokerage currently has a neutral rating on the medical research company's stock.

A number of other equities research analysts have also recently weighed in on CRL. UBS Group lowered their target price on shares of Charles River Laboratories International from $290.00 to $240.00 and set a buy rating on the stock in a research report on Thursday, August 8th. StockNews.com upgraded shares of Charles River Laboratories International from a hold rating to a buy rating in a research note on Tuesday, August 20th. TD Cowen reduced their target price on shares of Charles River Laboratories International from $228.00 to $203.00 and set a hold rating for the company in a report on Monday, August 12th. Mizuho started coverage on Charles River Laboratories International in a report on Friday, June 7th. They set a neutral rating and a $235.00 price target on the stock. Finally, The Goldman Sachs Group reduced their price objective on Charles River Laboratories International from $290.00 to $250.00 and set a buy rating for the company in a research note on Thursday, August 8th. Ten equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of Hold and a consensus target price of $230.93.

Charles River Laboratories International Trading Down 1.8 %

Shares of CRL stock traded down $3.83 on Friday, hitting $205.79. The stock had a trading volume of 1,153,737 shares, compared to its average volume of 591,938. The firm has a market capitalization of $10.60 billion, a P/E ratio of 24.21, a P/E/G ratio of 3.89 and a beta of 1.36. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.58 and a quick ratio of 1.21. The company's 50 day moving average price is $209.55 and its 200-day moving average price is $224.43. Charles River Laboratories International has a 1 year low of $161.65 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 EPS for the quarter, topping analysts' consensus estimates of $2.39 by $0.41. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.03 billion. Analysts anticipate that Charles River Laboratories International will post 10.01 earnings per share for the current year.

Charles River Laboratories International declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, August 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.

Institutional Investors Weigh In On Charles River Laboratories International

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Czech National Bank lifted its stake in shares of Charles River Laboratories International by 0.5% during the first quarter. Czech National Bank now owns 9,025 shares of the medical research company's stock worth $2,445,000 after purchasing an additional 41 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in Charles River Laboratories International by 1.0% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company's stock worth $914,000 after acquiring an additional 45 shares in the last quarter. American Trust boosted its holdings in Charles River Laboratories International by 5.9% in the 2nd quarter. American Trust now owns 976 shares of the medical research company's stock worth $202,000 after acquiring an additional 54 shares during the period. Tortoise Investment Management LLC boosted its holdings in Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock worth $27,000 after acquiring an additional 57 shares during the period. Finally, Dumont & Blake Investment Advisors LLC grew its position in Charles River Laboratories International by 1.4% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 4,415 shares of the medical research company's stock valued at $1,196,000 after acquiring an additional 62 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).